The STAT5b Pathway Defect and Autoimmunity by Takahiro Kanai et al.
REVIEW ARTICLE
published: 14 August 2012
doi: 10.3389/fimmu.2012.00234
The STAT5b pathway defect and autoimmunity
Takahiro Kanai †, Jennifer Jenks† and Kari Christine Nadeau*
Division of Immunology and Allergy, Department of Pediatrics, School of Medicine, Stanford University, Stanford, CA, USA
Edited by:
Rosa Bacchetta, Fondazione Centro
San Raffaele Del Monte Tabor, Italy
Reviewed by:
Michael Jordan, Cincinnati Children’s
Hospital/University of Cincinnati, USA
Rupali Das, Children’s Hospital of
Philadelphia, USA
*Correspondence:
Kari Christine Nadeau, Division of
Immunology and Allergy, Department
of Pediatrics, School of Medicine,
Stanford University, Stanford, CA
94305, USA.
e-mail: knadeau@stanford.edu
†Takahiro Kanai and Jennifer Jenks
contributed equally to this review.
The signal transducer and activator of transcription (STAT) 5b is a universal transcription fac-
tor that plays key biological roles in allergic diseases, immunodeficiencies, autoimmunities,
cancers, hematological diseases, growth disorders, and lung diseases. The identification
of distinct pathological manifestations of STAT5b deficiency in humans has highlighted the
critical role of the STAT5b pathway. Proper gene transcription at IL-2Rα, FOXP3, Bcl-2, and
growth hormone (GH) associated loci are thought to be associated with normal STAT5b tran-
scriptional activity.These genes are thought to play important roles in allergy/autoimmunity,
immunodeficiency, cancer/anemia, and growth, respectively. The STAT5A and STAT5B
genes are collocated on 17q11. Although these two monomeric proteins exhibit peptide
sequence similarities of >90%, it is known through observations of STAT5b deficient sub-
jects that STAT5a and STAT5b are not fully redundant in humans. Patients with STAT5b
deficiency have decreased numbers of regulatory CD4+CD25high T cell (Treg) despite their
STAT5a levels being normal. Prior studies on STAT5b deficient subjects have revealed
immunological aberrations associated with the following disease phenotype: modest lym-
phopenia and decreased populations of Treg, γ-δ T cells, and natural killer (NK) cells. Most
subjects with STAT5b deficiency show severe eczema, and autoimmune disease (juve-
nile idiopathic arthritis, autoimmune thyroiditis, idiopathic thrombocytic purpura) which are
thought to be associated withTreg dysfunction.We will review the likely pathophysiological
mechanisms associated with STAT5b deficiency.
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INTRODUCTION
The signal transducer and activator of transcription (STAT) 5b
is a universal transcription factor that plays key biological roles
in allergic disease, immunodeficiencies, autoimmunities, cancers,
hematological disease,growth disorders, and lung disease (Buggins
and Pepper, 2010; Nadeau et al., 2011).
There are several differences between human and mouse in
the roles of STAT5b (Nadeau et al., 2011). The identification of
STAT5b deficiency in humans, and the distinct and destructive
pathology associated with this deficiency has highlighted the criti-
cal role the STAT5b pathway. Research on the immunologic func-
tion of STAT5b has demonstrated its importance for the in vivo
accumulation of regulatory CD4+CD25high T cells (Treg) with
immunoregulatory function (Cohen et al., 2006; Nadeau et al.,
2011). The specific role that STAT5b plays in the pathogenesis of
the aforementioned diseases has led to suggestions that the tran-
scription factor might have potential as a novel diagnostic and/or
therapeutic target in some disease settings.
In this review, we summarize recent advances in our under-
standing of the STAT5b pathway in human mainly as well as the
autoimmune manifestations induced by the defects within it.
THE STAT5b PATHWAY
STAT5b GENE AND PROTEIN, AND NON-REDUNDANCY BETWEEN
STAT5a AND STAT5b
The STAT5B gene is collocated on 17q11.2 approximately 12 kb
apart from STAT5A (Figure 1). Both genes are regulated by a Sp-1
cis-element (Crispi et al., 2004).
Although STAT5a and STAT5b show peptide sequence similar-
ities of >90%, they differ by six amino acid in the DNA binding
domain and 20 amino acids in their carboxy termini (Boucheron
et al., 1998; Grimley et al., 1999; Soldaini et al., 2000; Wei et al.,
2008). Additional reports of a common disease phenotype specif-
ically associated with STAT5b deficiency in humans (but no such
phenotype associated with STAT5a deficiency) indicates that, at
least in humans, the roles of STAT5a and STAT5b are not fully
redundant (Nadeau et al., 2011).
Structural dissimilarities between the STAT5a and the STAT5b
on transactivation domains or subtle differences in the DNA bind-
ing affinities of STAT5 dimer pairs could influence gene regulation,
but cell-dependent asymmetries in the availability of phosphory-
lated STAT5a or STAT5b could also another factor. Signal atten-
uation by phosphatase action or classic feedback inhibition, or
truncated forms of STAT5b lacking in transactivation capacity,
may compete upstream for activation and diminish access of full
length molecules to DNA binding sites (Grimley et al., 1999). Thus,
both STAT5 proteins could bind to the same targets, and any dif-
ferences between STAT5a and STAT5b may arise from differential
expression or difference in kinetics of DNA binding (Grimley et al.,
1999).
UPSTREAM OF STAT5b: CYTOKINES AND THEIR RECEPTORS
Signal transducer and activator of transcription 5b is a common
downstream effector of the IL-2, -4, -7, -9, -13, -15, -21, growth
hormone (GH; Liu et al., 1997), erythropoietin, thrombopoietin,
and granulocyte colony-stimulating factor signaling molecules
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FIGURE 1 |The STAT5B gene is collocated on 17q11.2 approximately
12 kb apart from the STAT5A gene. The STAT5B gene is on the negative
strand, and the STAT5a gene is on the positive strand. The genomic size of
STAT5b is 58,700–77,229. The genomic size of STAT5a is approximately
24,000.
(Nadeau et al., 2011). Each cytokine has associated receptors, and
each receptor has associated Janus kinases (JAK). For example, the
IL-2 receptor is composed of an α chain (CD25),β chain (CD122),
and γ chain (CD132; Lin and Leonard, 2000). The β chain is asso-
ciated with JAK1 and JAK3 (Zhu et al., 1998) and the γ chain is
associated with JAK3 (Figure 2; Russell et al., 1995). The growth
hormone receptor (GHR) is associated with JAK2 (Hwa et al.,
2011).
The CD25 plays an important role as an integral component of
the high affinity IL-2 receptor. Its ligand, IL-2, is a cytokine known
for the role it plays in lymphocytic function, especially with rela-
tion to T cell biology. There are two functional receptors for IL-2:
one is a heterodimeric complex formed by theβ andγ chains, while
the other is a trimeric membrane-spanning complex composed of
the α,β, and γ subunits. The latter receptor has a higher affinity for
IL-2 than the former (Lin and Leonard, 2000). Additionally, defects
in STAT5b expression and function have been shown to result in
reduced expression of IL-2Rα, thereby potentially limiting cellular
response to IL-2 signaling (Cohen et al., 2006).
The engagement between cytokines and their cell surface recep-
tors results in subsequent activation of receptor-associated JAK
tyrosine kinase activity. Activated JAKs phosphorylate specific
tyrosine resides in the cytoplasmic domain of their associated
receptor,and these newly phosphorylated residues serve as docking
sites for STAT proteins (Figure 2; Grimley et al., 1999).
PHOSPHORYLATION OF STAT5b BY JAKs (MAINLY JAK1 AND 3)
Intracellular signal transduction pathways are essential for trans-
forming extracellular cytokine signaling into appropriate cellular
responses. The phosphorylation of STAT molecules is a key com-
ponent in the JAK/STAT signal transduction pathway (Xu and Qu,
2008).
Cytokine engagement of membrane-associated receptors
brings receptor subunits into proximal relationships necessary
for JAK autophosphorylation (Figure 2). Cytoplasmic STAT
monomers are subsequently able to bind the phosphotyrosine
residues on engaged cytokine receptors through the highly con-
served SH2 domain located on all proteins of the STAT family
(Figure 3).
As a result of this docking, JAK and STAT molecules are brought
into close enough proximity to allow for JAK phosphorylation,
and therefore activation, of STAT molecules. In the case of STAT5,
phosphorylated STAT5a and/or STAT5b then homo- or hetero-
dimerize (sometime tetramaerization; John et al., 1999; Soldaini
et al., 2000; Mandal et al., 2011) by each SH2 domain, leave
the receptor, and translocate to the nucleus where they act as a
transcriptional activator for each target gene (Levy and Darnell,
2002).
DOWNSTREAM OF THE STAT5b PATHWAY
Signal transducer and activator of transcription 5b dimers translo-
cate into the nucleus and bind to specific regions thought to
be associated with transcription of FOXP3, CD25, Bcl-2, IGF-1
(Nadeau et al., 2011). Reports indicate that STAT5b may preferen-
tially interact with different DNA binding sites depending on the
cell type considered.
Fork-head box P3 (FOXP3): a key transcription factor essential for
Treg cell development and function
The transcription factor FOXP3 is critical for the thymic devel-
opment of Tregs (Sakaguchi et al., 2008). In mice, CD4+CD25+
peripheral T cells and CD4+CD25+CD8− thymocytes express
Foxp3 and are considered to be immunoregulatory, whereas other
thymocytes/T cells, either in a resting or activated state, do not
(Fontenot et al., 2003; Hori et al., 2003; Khattri et al., 2003;
Sakaguchi et al., 2008).
Studies investigating the effects of FOXP3 suppression report
complications associated with Treg dysfunction to be a main
pathological consequence. Mutations of the FOXP3 gene were
found to be the cause of an IPEX (immune dysregulation, polyen-
docrinopathy, enteropathy, X-linked syndrome), which is charac-
terized by autoimmune disease in multiple endocrine organs (as in
type I diabetes and thyroiditis), inflammatory bowel disease, and
severe allergy (Chatila et al., 2000; Bennett et al., 2001; Wildin et al.,
2001). Deletion or dysfunction of FOXP3 causes impaired func-
tion and/or homeostasis of Tregs, and has been implicated in the
development of several common autoimmune and inflammatory
diseases (Campbell and Koch, 2011).
The essential role of CD25 in Treg development and function
High expression of CD25 is considered to be a marker of Tregs
(Sakaguchi et al., 1995) and studies have elaborated on this con-
cept, demonstrating that the IL-2Rα serves not only as a marker
for natural Treg, but also, as a protein essential for its development
and function (Sakaguchi et al., 2008). The importance of CD25
in the development of a normal immune response is emphasized
by the finding that a truncation mutant of CD25 results in an
immunodeficiency in humans characterized by an increased sus-
ceptibility to viral, bacterial, and fungal infection (Sharfe et al.,
1997). In addition, gene targeting analysis also reveals that CD25
deficient mice exhibit autoimmunity (Willerford et al., 1995).
While CD25 contributes to IL-2 binding affinity and not to the
recruitment of signaling molecules (Lin and Leonard, 2000) its role
as a component of the high affinity IL-2 receptor makes it indis-
pensable for the activation of cell signaling pathways associated
with IL-2 signal transduction (Sakaguchi et al., 2008).
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FIGURE 2 |This shows the schema of STAT5a and/or STAT5b activation.
The engagement between a cytokine and its cell surface receptor results in
subsequent activation of receptor-associated JAK. Activated JAK
phosphorylates specific tyrosine resides in the cytoplasmic domain of the
receptor which in turn serves as the docking sites for STAT5a and/or STAT5b.
STAT5a and/or STAT5b are recruited to the phosphorylated receptor and
subsequently phosphorylated by JAKs. The phosphorylated STAT5a and/or
STAT5b dimerize, leave the receptor, and translocate to the nucleus.
Bcl-2 is an apoptotic inhibitor protein
Bcl-2 is an apoptosis inhibitor protein. Most cell death in verte-
brates occurs via the mitochondrial pathway of apoptosis, in which
Bcl-2 and other anti-apoptotic proteins (Bcl-xL, Bcl-w, Mcl-1, and
Bfl-1/A1) are key effectors (Llambi and Green, 2011). Aberrant
regulation of Bcl-2 has been reported to cause or correlate with
autoimmunity or cancer, particularly leukemia (Buggins and Pep-
per, 2010; Tischner et al., 2010). Deletion of self-reactive immune
cells occurs through this apoptotic pathway and is necessary for
the maintenance of immune tolerance (Tischner et al., 2010).
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FIGURE 3 | Schematic structures of STAT5a and STAT5b. STAT5a and STAT5b differ in the C terminal domain. The dimerization occurs through the interaction
between the SH2 domains.
Overexpression of Bcl-2 has been noted in patients with systemic
lupus erythematosus (Tischner et al., 2010). In malignant dis-
eases, decreased rate of apoptotic cell death is also found to be
responsible in the proliferative process (Ulukaya et al., 2011).
Insulin-like growth factor-I and Insulin-like growth factor binding
protein-3 play an important role in fat metabolism and skeletal
development
Insulin-like growth factor-I promotes skeletal development and
fat metabolism, and insulin-like growth factor binding protein-3
(IGFBP-3) acts as a negative regulator for IGF-I signaling (Kawai
and Rosen, 2010).
The activation of IGF-I is initiated by the interaction of circulat-
ing GH with the GHR. The cytoplasmic domain of GHR associates
preferentially with JAK2. Activation of JAK2 by GHR engagement
leads to the activation of STAT5b (Hwa et al., 2011).
In humans, serum IGF-I concentrations have a positive corre-
lation with skeletal mass (Langlois et al., 1998). A report on the
disease characteristics of STAT5b deficiency in humans highlights
low serum IGF-1 as one defining clinical feature of the disease
(Hwa et al., 2004; Nadeau et al., 2011). STAT5b deficient patients
also exhibit stunted growth and poor response to GH therapy
(Nadeau et al., 2011).
IGF-I was also reported as a critical factor for adipogenesis
(Kawai and Rosen, 2010). The lack of this factor results in a defect
in adipose tissue formation by mitogen-activated protein kinase
deactivation in conjunction with GH (Boney et al., 2000; Hwa
et al., 2011).
IGFBP-3 suppresses adipogenesis independent of IGF-I bind-
ing (Chan et al., 2009) and reduces bone mineral density (Kawai
and Rosen, 2010).
HUMAN STAT5b PATHWAY DEFECT AND AUTOIMMUNITY
Human STAT5b deficiency is a recently identified, rare autosomal
recessive disease that involves both severe GH-resistant growth
failure and severe primary immunodeficiency. It was first dis-
covered in patients with dwarfism associated with normal levels
of serum GH, but very low levels of IGF-I (Kofoed et al., 2003;
Bernasconi et al., 2006; Chia et al., 2006). Affected individu-
als also exhibited recurrent infections, chronic diarrhea, eczema,
and/or lymphocytic interstitial pneumonitis (Kofoed et al., 2003;
Bernasconi et al., 2006; Chia et al., 2006). Immunophenotyping of
these patients have revealed modest lymphopenia and decreased
populations of Treg, γ-δ T cells, and natural killer (NK) cells
(Bernasconi et al., 2006; Cohen et al., 2006). There are currently
10 published cases of STAT5b deficiency (Table 1; Nadeau et al.,
2011). Ongoing research efforts aim to identify the molecular
mechanisms of STAT5b in postnatal growth and immunity.
Previous cases
The first case of a STAT5b mutation was reported in 2003, in
a 16-year-old female with severe growth retardation (−7.5 SD)
and pulmonary complications (Kofoed et al., 2003). The reported
missense mutation (p.A630P) disrupted the core of anti-parallel
β-sheets that enable phosphate-binding, causing aberrant folding
(Chen et al., 1998) aggregation of mutant STAT5b protein, and
loss of thermodynamic stability (Chia et al., 2006; Fang et al.,
2006). The patient presented with early onset lymphocytic inter-
stitial pneumonitis, chronic lung disease, hemorrhagic varicella,
atopy, and autoimmune disease (Kofoed et al., 2003). At age 7, she
developed lymphocytic interstitial pneumonia and after receiv-
ing potent immunosuppressive therapy, had two major infectious
complications – severe varicella-zoster virus infection and Pneu-
mocystis jiroveci pneumonia. Another biopsy at age 10 also indi-
cated lymphoid interstitial pneumonia, and P. carinii was isolated
from the tissue. Later studies revealed decreased numbers of Treg
and reduced Treg suppressive function (Cohen et al., 2006).
In 2005, a second case of a STAT5b deficiency was identified
in a 16-year-old Turkish female with severe growth failure, GHI,
atopic dermatitis, pruritic skin lesions, primary idiopathic pul-
monary fibrosis with diffuse lung involvement, and autoimmune
disease, as well as bleeding diathesis caused by defective thrombo-
cyte aggregation, preventing a potential lung biopsy (Hwa et al.,
2005). Sequencing of the STAT5b gene revealed a novel homozy-
gous frameshift mutation (c.1191insG) that led to protein termi-
nation (p.N398EfsX16) and consequent lack of immunodetectable
STAT5b protein (Hwa et al., 2005).
Another case was identified in 2006 in a 16-year-old female
with severe postnatal growth failure, GHI, and immunodeficiency
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(Bernasconi et al., 2006). Pulmonary-function tests showed mixed,
restrictive, and obstructive moderate ventilative insufficiency, but
no lung biopsy was performed. Notably, this case was the first
to identify a role for STAT5b not only in the human GH signal-
ing cascade, but also in the cytokine-mediated immune response.
The STAT5b deficient patient had moderate T cell lymphopenia,
normal CD4/CD8 ratios, and very low numbers of NK cells and
γ-δ T cells, and the T cells presented a chronically hyperactivated
phenotype (Bernasconi et al., 2006).
Since 2012, five other mutations have been published on a
total of seven additional subjects (Table 1). Lung pathology has
been common among these patients (8 of 10), but of these
remaining seven subjects, only a few have received lung biop-
sies. A STAT5b deficient male with the mutation 424_427del
received a biopsy at 6 years of age that indicated severe lympho-
cytic interstitial pneumonitis. Considered together, these studies
have firmly established a correlation between STAT5b deficiency
and immune dysfunction, in addition to GHI and severe growth
problems.
Clinical manifestations and diagnosis
Signal transducer and activator of transcription 5b deficiency
should be considered in the differential diagnosis of a patient
who has normal gestational growth and birth size but acquires
significantly short stature and recurrent infections. This pattern
of growth is typical of patients with GHI. Height may range from
−3.0 to−9.9 SD in girls and boys, respectively (Table 1).
Regarding hormone evaluations, all described patients have
had normal levels of GH at baseline, but after stimulation, GH
concentrations were often elevated (Table 1). In contrast, serum
IGF-I, IGFBP-3, and acid labile subunit concentrations were low,
and even upon administration of GH, remained low. Elevated
prolactin levels were also observed in patients with recorded
concentrations.
Most patients have displayed evidence of immune dysfunc-
tion, including atopic disease, chronic lung disease, viral infections,
and/or autoimmune diatheses. Often present in childhood, severe
pulmonary disease is of particular concern, as it has affected 8 of
the 10 known STAT5b deficient patients and two patients have died
of respiratory failure. For all cases of lung pathology except for that
of Patient #5, an axial chest CT scan has shown increased inter-
stitial patterns and ground-glass appearance. These pulmonary
lesions are T cell predominant, despite peripheral lymphopenia.
In most cases, severe eczema, thrombocytopenic purpura, and/or
autoimmune disease, such as juvenile idiopathic arthritis, were
present in addition to severe lung disease. However, it should be
noted that 1 of the 10 subjects to date has less severe immune
dysfunction. Congenital ichthyosis was diagnosed at birth, and
the patient had hemorrhagic varicella at 16 years of age but had no
history of pulmonary of immunological problems (Vidarsdottir
et al., 2006).
Previous immunological studies have established the impor-
tance of STAT5b proteins in the development, homeostasis, and
proliferation of different lymphocyte populations. Immune reper-
toires of STAT5b deficient patients have shown moderate lym-
phopenia, with very low numbers of NK and T cells, as well as Treg
dysfunction. Furthermore, B cell populations and immunoglobu-
lin G levels in at least patient are normal to elevated, as consistent
with autoimmune disease symptoms (Cohen et al., 2006).
Disease management
In order to improve clinical outcomes for patients with STAT5b
deficiency, optimizing early diagnosis in these patients is critical.
To date, overall management of STAT5b deficiency is still unclear.
GH therapy is ineffective due to the patients’ GHI. It is presumed
that IGF-I therapy may be an effective treatment, unless the pres-
ence of chronic infection limits the growth response. However, to
date, no clinical trials of IGF-I therapy have been performed in
these patients.
Patients should be closely monitored for signs and symptoms
of immunodeficiency. Infections such as severe varicella or recur-
rent pneumonias should be aggressively treated with appropriate
antimicrobial therapies. Patients with autoimmune conditions,
atopic diseases, or pulmonary fibrosis may also require antipro-
liferatives or immunosuppressants, such as steroids, to address
overactive effector T cell responses. Because severe chronic lung
disease in this patient population often leads to high morbid-
ity and mortality, patients should be carefully monitored with
pulmonary-function tests and physical examinations, which may
improve treatment options to decrease the lung disease severity.
Although current management of STAT5b deficiency is pri-
marily dictated by specific end-organ pathology, current research
is addressing the possibility of enhancing STAT5b and/or STAT5a
pathways (Zeiser et al., 2008; Strauss et al., 2009). Future therapy
may be expected to prevent and reflect rationally based drug design
to enhance certain drug targets in the STAT5b and/or STAT5a
pathways.
CONCLUSION
In this review, we focused on the STAT5b pathway and the mech-
anisms by which defects in protein structure and or expression
might result in autoimmunity. A better understanding of STAT5b
and its distinct biological functions is necessary for the develop-
ment of new diagnostic and therapeutic approaches for treating
patients suffering from its deficiency.
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